Influence of dose and schedule on the therapeutic efficacy of 131I-labelled monoclonal antibody 139H2 in a human ovarian cancer xenograft model

C. F M Molthoff, H. M. Pinedo, H. M M Schluper, E. Boven

Research output: Contribution to journalArticle

Abstract

The therapeutic efficacy of various doses and schedules of 131I-labelled anti-episialin monoclonal antibody (MAb) 139H2 was assessed in the NIH:OVCAR-3 human ovarian cancer xenograft model. Radioimmunotherapy was started at the time s.c. tumors were well established (100 to 300 mm3). The anti-tumor effects induced by i.v. injections of 131I-MAb 139H2 were dose- and schedule-dependent. Optimal growth inhibition and long-lasting complete tumor regressions were obtained with 2 injections of 500, 700 or 750 μCi 131I-MAb 139H2 per mouse given with a 2-week interval. The percentage of tumors with more than 50% reduction of their initial volume after treatment with a total dose of 1,000 μCi 131I-MAb 139H2 per mouse, given as 10 injections of 100 μCi (3 x/week), 4 injections of 250 μCi (2 x/week), 10 injections of 100 μCi (5 x/week) within a period of 3 weeks, or 2 injections of 500 μCi with a 2-week interval, was 9%, 40%, 64% and 75% respectively. Unlabelled MAb 139H2 did not affect tumor growth, while the effects of 131I-control MAb were minor and transient. 131I-MAb 139H2 treatment did not select for outgrowth of episialin-negative cells in the OVCAR-3 xenografts. Highest absorbed doses of whole-body-radiation were calculated for 2 injections (500 to 750 μCi 131I-MAb 139H2) given with the 2-week interval. The radiation dose to the tumor after a single injection of 500 μCi 131I-MAb 139H2 was 1,300 cGy over 7 days, which appeared slightly lower than the dose calculated after administration of a tracer dose of iodinated MAb 139H2.

Original languageEnglish (US)
Pages (from-to)474-480
Number of pages7
JournalInternational Journal of Cancer
Volume50
Issue number3
StatePublished - 1992
Externally publishedYes

Fingerprint

Heterografts
Ovarian Neoplasms
Appointments and Schedules
Monoclonal Antibodies
Injections
Therapeutics
Mucin-1
Neoplasms
Radioimmunotherapy
Whole-Body Irradiation
Growth
Radiation

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Influence of dose and schedule on the therapeutic efficacy of 131I-labelled monoclonal antibody 139H2 in a human ovarian cancer xenograft model. / Molthoff, C. F M; Pinedo, H. M.; Schluper, H. M M; Boven, E.

In: International Journal of Cancer, Vol. 50, No. 3, 1992, p. 474-480.

Research output: Contribution to journalArticle

@article{c32ba1c3adad43a6935121a7dfaa379b,
title = "Influence of dose and schedule on the therapeutic efficacy of 131I-labelled monoclonal antibody 139H2 in a human ovarian cancer xenograft model",
abstract = "The therapeutic efficacy of various doses and schedules of 131I-labelled anti-episialin monoclonal antibody (MAb) 139H2 was assessed in the NIH:OVCAR-3 human ovarian cancer xenograft model. Radioimmunotherapy was started at the time s.c. tumors were well established (100 to 300 mm3). The anti-tumor effects induced by i.v. injections of 131I-MAb 139H2 were dose- and schedule-dependent. Optimal growth inhibition and long-lasting complete tumor regressions were obtained with 2 injections of 500, 700 or 750 μCi 131I-MAb 139H2 per mouse given with a 2-week interval. The percentage of tumors with more than 50{\%} reduction of their initial volume after treatment with a total dose of 1,000 μCi 131I-MAb 139H2 per mouse, given as 10 injections of 100 μCi (3 x/week), 4 injections of 250 μCi (2 x/week), 10 injections of 100 μCi (5 x/week) within a period of 3 weeks, or 2 injections of 500 μCi with a 2-week interval, was 9{\%}, 40{\%}, 64{\%} and 75{\%} respectively. Unlabelled MAb 139H2 did not affect tumor growth, while the effects of 131I-control MAb were minor and transient. 131I-MAb 139H2 treatment did not select for outgrowth of episialin-negative cells in the OVCAR-3 xenografts. Highest absorbed doses of whole-body-radiation were calculated for 2 injections (500 to 750 μCi 131I-MAb 139H2) given with the 2-week interval. The radiation dose to the tumor after a single injection of 500 μCi 131I-MAb 139H2 was 1,300 cGy over 7 days, which appeared slightly lower than the dose calculated after administration of a tracer dose of iodinated MAb 139H2.",
author = "Molthoff, {C. F M} and Pinedo, {H. M.} and Schluper, {H. M M} and E. Boven",
year = "1992",
language = "English (US)",
volume = "50",
pages = "474--480",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - Influence of dose and schedule on the therapeutic efficacy of 131I-labelled monoclonal antibody 139H2 in a human ovarian cancer xenograft model

AU - Molthoff, C. F M

AU - Pinedo, H. M.

AU - Schluper, H. M M

AU - Boven, E.

PY - 1992

Y1 - 1992

N2 - The therapeutic efficacy of various doses and schedules of 131I-labelled anti-episialin monoclonal antibody (MAb) 139H2 was assessed in the NIH:OVCAR-3 human ovarian cancer xenograft model. Radioimmunotherapy was started at the time s.c. tumors were well established (100 to 300 mm3). The anti-tumor effects induced by i.v. injections of 131I-MAb 139H2 were dose- and schedule-dependent. Optimal growth inhibition and long-lasting complete tumor regressions were obtained with 2 injections of 500, 700 or 750 μCi 131I-MAb 139H2 per mouse given with a 2-week interval. The percentage of tumors with more than 50% reduction of their initial volume after treatment with a total dose of 1,000 μCi 131I-MAb 139H2 per mouse, given as 10 injections of 100 μCi (3 x/week), 4 injections of 250 μCi (2 x/week), 10 injections of 100 μCi (5 x/week) within a period of 3 weeks, or 2 injections of 500 μCi with a 2-week interval, was 9%, 40%, 64% and 75% respectively. Unlabelled MAb 139H2 did not affect tumor growth, while the effects of 131I-control MAb were minor and transient. 131I-MAb 139H2 treatment did not select for outgrowth of episialin-negative cells in the OVCAR-3 xenografts. Highest absorbed doses of whole-body-radiation were calculated for 2 injections (500 to 750 μCi 131I-MAb 139H2) given with the 2-week interval. The radiation dose to the tumor after a single injection of 500 μCi 131I-MAb 139H2 was 1,300 cGy over 7 days, which appeared slightly lower than the dose calculated after administration of a tracer dose of iodinated MAb 139H2.

AB - The therapeutic efficacy of various doses and schedules of 131I-labelled anti-episialin monoclonal antibody (MAb) 139H2 was assessed in the NIH:OVCAR-3 human ovarian cancer xenograft model. Radioimmunotherapy was started at the time s.c. tumors were well established (100 to 300 mm3). The anti-tumor effects induced by i.v. injections of 131I-MAb 139H2 were dose- and schedule-dependent. Optimal growth inhibition and long-lasting complete tumor regressions were obtained with 2 injections of 500, 700 or 750 μCi 131I-MAb 139H2 per mouse given with a 2-week interval. The percentage of tumors with more than 50% reduction of their initial volume after treatment with a total dose of 1,000 μCi 131I-MAb 139H2 per mouse, given as 10 injections of 100 μCi (3 x/week), 4 injections of 250 μCi (2 x/week), 10 injections of 100 μCi (5 x/week) within a period of 3 weeks, or 2 injections of 500 μCi with a 2-week interval, was 9%, 40%, 64% and 75% respectively. Unlabelled MAb 139H2 did not affect tumor growth, while the effects of 131I-control MAb were minor and transient. 131I-MAb 139H2 treatment did not select for outgrowth of episialin-negative cells in the OVCAR-3 xenografts. Highest absorbed doses of whole-body-radiation were calculated for 2 injections (500 to 750 μCi 131I-MAb 139H2) given with the 2-week interval. The radiation dose to the tumor after a single injection of 500 μCi 131I-MAb 139H2 was 1,300 cGy over 7 days, which appeared slightly lower than the dose calculated after administration of a tracer dose of iodinated MAb 139H2.

UR - http://www.scopus.com/inward/record.url?scp=0026565671&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026565671&partnerID=8YFLogxK

M3 - Article

VL - 50

SP - 474

EP - 480

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 3

ER -